Fentora Patent Expiration

Fentora is a drug owned by Cephalon Llc. It is protected by 9 US drug patents filed from 2013 to 2014. Out of these, 4 drug patents are active and 5 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 15, 2028. Details of Fentora's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7862832 Generally linear effervescent oral fentanyl dosage form and methods of administering
Jun, 2028

(3 years from now)

Active
US7862833 Effervescent oral opiate dosage forms and methods of administering opiates
Jun, 2028

(3 years from now)

Active
US8092832 Generally linear effervescent oral fentanyl dosage form and methods of administering
Dec, 2024

(11 days from now)

Active
US8119158 Effervescent oral fentanyl dosage form and methods of administering fentanyl
Dec, 2024

(11 days from now)

Active
US6974590 Sublingual buccal effervescent
Mar, 2019

(5 years ago)

Expired
US6200604 Sublingual buccal effervescent
Mar, 2019

(5 years ago)

Expired
US8765100 Transmucosal effervescent
Mar, 2019

(5 years ago)

Expired
US8728441 Sublingual buccal effervescent
Mar, 2019

(5 years ago)

Expired
US8753611 Sublingual buccal effervescent
Mar, 2019

(5 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fentora's patents.

Given below is the list of recent legal activities going on the following patents of Fentora.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 21 Jul, 2023 US8119158 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 20 Jun, 2023 US8092832
Expire Patent 08 Aug, 2022 US8765100
Expire Patent 25 Jul, 2022 US8753611
Payment of Maintenance Fee, 12th Year, Large Entity 27 Jun, 2022 US7862832 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 27 Jun, 2022 US7862833 (Litigated)
Maintenance Fee Reminder Mailed 21 Feb, 2022 US8765100
Maintenance Fee Reminder Mailed 07 Feb, 2022 US8753611
Payment of Maintenance Fee, 8th Year, Large Entity 13 Aug, 2019 US8119158 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 02 Jul, 2019 US8092832

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Fentora is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fentora's family patents as well as insights into ongoing legal events on those patents.

Fentora's Family Patents

Fentora has patent protection in a total of 29 countries. It's US patent count contributes only to 21.5% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Fentora.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Fentora's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 15, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Fentora Generic API suppliers:

Fentanyl Citrate is the generic name for the brand Fentora. 9 different companies have already filed for the generic of Fentora, with Specgx Llc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Fentora's generic

How can I launch a generic of Fentora before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Fentora's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Fentora's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Fentora -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.6 mg and 0.8 mg 13 Nov, 2007 1 07 Jan, 2011 26 Mar, 2019 Extinguished Deferred

Alternative Brands for Fentora

Fentora which is used for managing breakthrough pain in cancer patients., has several other brand drugs in the same treatment category and using the same active ingredient (Fentanyl Citrate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Adalvo
Onsolis

(uses Fentanyl Citrate)

Used for managing breakthrough pain in patients with cancer.
Btcp Pharma
Lazanda

(uses Fentanyl Citrate)

Used for managing breakthrough pain in cancer patients who are already receiving and tolerant to opioid therapy.
Sentynl Theraps Inc
Abstral

(uses Fentanyl Citrate)

Used for managing breakthrough pain in cancer patients.

Apart from brand drugs containing the same ingredient, some generics have also been filed for Fentanyl Citrate, Fentora's active ingredient. Check the complete list of approved generic manufacturers for Fentora





About Fentora

Fentora is a drug owned by Cephalon Llc. It is used for managing breakthrough pain in cancer patients. Fentora uses Fentanyl Citrate as an active ingredient. Fentora was launched by Cephalon in 2006.

Approval Date:

Fentora was approved by FDA for market use on 25 September, 2006.

Active Ingredient:

Fentora uses Fentanyl Citrate as the active ingredient. Check out other Drugs and Companies using Fentanyl Citrate ingredient

Treatment:

Fentora is used for managing breakthrough pain in cancer patients.

Dosage:

Fentora is available in tablet form for buccal, sublingual use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.2MG BASE TABLET Discontinued BUCCAL, SUBLINGUAL
EQ 0.1MG BASE TABLET Discontinued BUCCAL, SUBLINGUAL
EQ 0.6MG BASE TABLET Discontinued BUCCAL, SUBLINGUAL
EQ 0.4MG BASE TABLET Discontinued BUCCAL, SUBLINGUAL
EQ 0.8MG BASE TABLET Discontinued BUCCAL, SUBLINGUAL
EQ 0.3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued BUCCAL, SUBLINGUAL